Shai Meretzki - Bonus BioGroup CEO, Founder
| BBIXF Stock | USD 0.02 0.00 0.00% |
Insider
Shai Meretzki is CEO, Founder of Bonus BioGroup
| Age | 54 |
| Phone | 972 7 320 67104 |
| Web | https://www.bonusbiogroup.com |
Bonus BioGroup Management Efficiency
The company has return on total asset (ROA) of (0.0636) % which means that it has lost $0.0636 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.5522) %, meaning that it generated substantial loss on money invested by shareholders. Bonus BioGroup's management efficiency ratios could be used to measure how well Bonus BioGroup manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Pascalyne Wilson | Cellectis SA | N/A | |
| Valerie Cros | Cellectis SA | N/A | |
| Greg Leszczynski | Covalon Technologies | N/A | |
| Jason Gorel | Covalon Technologies | N/A | |
| Mark Doolittle | Covalon Technologies | N/A | |
| Dr MBA | Cellectis SA | 46 | |
| Elaine Zhang | Covalon Technologies | N/A | |
| Simon Smith | Covalon Technologies | N/A | |
| Hamed Abbasian | Covalon Technologies | N/A | |
| Gerry Arambula | Covalon Technologies | N/A | |
| Jay Carlson | Mosaic Immunoengineering | N/A | |
| Nicole Steinmetz | Mosaic Immunoengineering | 43 | |
| Jean Epinat | Cellectis SA | N/A | |
| Steven King | Mosaic Immunoengineering | 59 | |
| Joseph MPH | Mosaic Immunoengineering | 50 | |
| Cyril Empig | Mosaic Immunoengineering | N/A | |
| Marvin MD | Mosaic Immunoengineering | 79 | |
| MSc MSc | Cellectis SA | 54 | |
| Paul CPA | Mosaic Immunoengineering | 55 | |
| Kyung NamWortman | Cellectis SA | 53 | |
| Ron Hebert | Covalon Technologies | N/A | |
Management Performance
| Return On Equity | -0.55 | |||
| Return On Asset | -0.0636 |
Bonus BioGroup Leadership Team
Elected by the shareholders, the Bonus BioGroup's board of directors comprises two types of representatives: Bonus BioGroup inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bonus. The board's role is to monitor Bonus BioGroup's management team and ensure that shareholders' interests are well served. Bonus BioGroup's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bonus BioGroup's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph MBA, Ex Chairman | ||
| Vered Kivity, Head Affairs | ||
| Shai Meretzki, CEO, Founder | ||
| Yoni CPA, Chief Officer |
Bonus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Bonus BioGroup a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.55 | |||
| Return On Asset | -0.0636 | |||
| Current Valuation | 48.99 M | |||
| Shares Outstanding | 1.17 B | |||
| Shares Owned By Insiders | 49.72 % | |||
| Shares Owned By Institutions | 0.09 % | |||
| Price To Book | 4.05 X | |||
| EBITDA | (88.03 M) | |||
| Net Income | (90.08 M) | |||
| Debt To Equity | 0.15 % |
Currently Active Assets on Macroaxis
Other Information on Investing in Bonus Pink Sheet
Bonus BioGroup financial ratios help investors to determine whether Bonus Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bonus with respect to the benefits of owning Bonus BioGroup security.